Fig. 3: In vitro and in vivo effects of SSTR2 agonists on the C666-1 NPC cell line. | Nature Communications

Fig. 3: In vitro and in vivo effects of SSTR2 agonists on the C666-1 NPC cell line.

From: Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy

Fig. 3

a Immunohistochemical characterization of C666-1, NPC43, and C17 cell lines cultured in vitro and from xenografted C666-1, C15, C17, or C18 tumor tissues (scale bar 100 µm); Replication n = 2. b In vitro dose response curves and half-maximal effective concentration (EC50 values) of the indicated SSTR agonists on C666-1, NPC43, and C17 cells. EC50 = half-maximal effective concentration. c Growth curves of C666-1 tumors in nude mice treated with vehicle (n = 9), octreotide (n = 9), or PEN-221 (n = 8). The dotted lines indicate the time points of drug injection. d Kaplan–Meier curves of athymic nude mice with C666-1 tumors, treated with vehicle control (n = 9), octreotide (n = 9), or PEN-221 (n = 8), with dotted lines showing time points of drug or vehicle injection (*p = 0.0368; two-sided Log-rank Mantel-Cox test). e Geneset enrichment analysis reveals upregulation of senescence pathways 24 h post lanreotide treatment (left), and upregulation of apoptosis and mitotic spindle assembly pathways 24 h post-PEN-221 treatment (right) in treated vs untreated cell lines. f mRNA sequencing analysis of C666-1 cells treated in vitro (72 h with PEN-221) reveals downregulation of SSTR2 expression (two-sided Wald test, adjusted p = 3.9e-7). Center line displays the median, boxes display the interquartile range. Whiskers display 1.5× the interquartile range. Source Data are provided as a Source data file.

Back to article page